Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in mind, Norstella surveyed 125 senior decision-makers in the life sciences industry on their perceptions and expectations of AI to understand current AI adoption trends in addition to the future impact of AI on pharmaceutical R&D. The following infographic provides a snapshot of the survey’s key results.
Norstella goes beyond the hype to address real-world implications of advanced technologies that will help to inform and improve the development of new treatments for patients in need. To learn more about Norstella’s AI capabilities, visit: Our solutions | Norstella
